Giant Cell Arteritis

• EMA approval · 2026-08-21
  EMA Authorised: Tuyory — Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)

  EMA authorised Tuyory from Chemical Works of Gedeon Richter Plc. for multiple indications including rheumatoid arthritis, juvenile arthritis…

• EMA approval · 2026-08-19
  EMA Authorised: Tyenne (tocilizumab) — Fresenius Kabi Deutschland GmbH

  Tyenne (tocilizumab) has been authorised by the EMA for multiple indications including rheumatoid arthritis, cytokine release syndrome, juve…

• EMA approval · 2026-08-13
  EMA Authorised: RoActemra (tocilizumab) — Roche Registration GmbH

  RoActemra (tocilizumab) has been authorised by the European Medicines Agency for multiple indications including rheumatoid arthritis, juveni…

• EMA approval · 2026-07-15
  EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG

  Rinvoq (upadacitinib) has been authorised by the EMA for multiple inflammatory diseases including rheumatoid arthritis, psoriatic arthritis,…

• EMA approval · 2026-06-15
  EMA Authorised: Tuyory — Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)

  Tuyory has been authorised by the EMA for multiple indications including rheumatoid arthritis, juvenile arthritis, cytokine release syndrome…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA approval · 2026-06-09
  EMA Authorised: Rinvoq (upadacitinib) — AbbVie Deutschland GmbH & Co. KG

  EU authorization of Rinvoq (upadacitinib) by AbbVie Deutschland for multiple inflammatory indications including rheumatoid arthritis, psoria…

• EMA approval · 2026-04-01
  EMA Authorised: RoActemra (tocilizumab) — Roche Registration GmbH

  EMA authorised RoActemra (tocilizumab) for multiple indications, including rheumatoid arthritis, juvenile idiopathic arthritis, cytokine rel…

• FDA approval · 2026-01-14
  FDA Approved: AVTOZMA — Supplemental Application (CELLTRION USA, Inc.)

  FDA approves a supplemental application for AVTOZMA (tocilizumab) filed by Celltrion USA, Inc.

• FDA approval · 2025-12-10
  FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)

  FDA approved a supplemental application for ACTEMRA (tocilizumab) submitted by Genentech, Inc.

• EMA approval · 2025-10-02
  EMA Authorised: Tyenne (tocilizumab) — Fresenius Kabi Deutschland GmbH

  EMA authorised Tyenne (tocilizumab) by Fresenius Kabi Deutschland GmbH for multiple indications, including rheumatoid arthritis, juvenile id…

• FDA approval · 2025-05-12
  FDA Approved: TYENNE — Supplemental Application (Fresenius Kabi USA, LLC)

  FDA approved a supplemental application for TYENNE (tocilizumab-azg) from Fresenius Kabi USA, LLC.

• FDA approval · 2025-03-13
  FDA Approved: TYENNE — Supplemental Application (Fresenius Kabi USA, LLC)

  FDA approved a supplemental application for TYENNE (tocilizumab-AAZG) from Fresenius Kabi USA, LLC.

• FDA approval · 2024-03-05
  FDA Approved: TYENNE — Original Application (Fresenius Kabi USA, LLC)

  FDA approved TYENNE (tocilizumab-AAZG) from Fresenius Kabi USA, LLC under an Original Application.

• FDA approval · 2021-10-22
  FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)

  FDA approved a supplemental application for Actemra (tocilizumab) from Genentech, expanding its labeling and/or indications. The action conf…

• FDA approval · 2019-06-11
  FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)

  FDA approved a supplemental application for Actemra (tocilizumab) filed by Genentech, Inc., resulting in an approved update to the product's…

• FDA approval · 2017-05-22
  FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)

  FDA approved a supplemental application for ACTEMRA (tocilizumab) submitted by Genentech, Inc. The supplementary filing status is AP (approv…

• FDA approval · 2014-11-13
  FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)

  The FDA approved a supplemental application for ACTEMRA (tocilizumab) submitted by Genentech, Inc. This action involves an approved product …

• FDA approval · 2012-08-13
  FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)

  FDA approved a supplemental application for Actemra (tocilizumab) submitted by Genentech, broadening its labeling.